Endometrin is a drug owned by Ferring Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 17, 2019. Details of Endometrin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7320800 | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(5 years ago) |
Expired
|
| US7393543 | Vaginally administratable progesterone-containing tablets and method for preparing same |
Nov, 2019
(5 years ago) |
Expired
|
| US7300664 | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(5 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Endometrin's patents.
Latest Legal Activities on Endometrin's Patents
Given below is the list of recent legal activities going on the following patents of Endometrin.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 24 Dec, 2019 | US7393543 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Jul, 2019 | US7320800 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 May, 2019 | US7300664 |
| Post Issue Communication - Certificate of Correction | 28 Oct, 2009 | US7393543 |
| Correspondence Address Change
Critical | 24 Aug, 2009 | US7393543 |
| Correspondence Address Change
Critical | 24 Aug, 2009 | US7320800 |
| Correspondence Address Change
Critical | 24 Aug, 2009 | US7300664 |
| Recordation of Patent Grant Mailed
Critical | 01 Jul, 2008 | US7393543 |
| Patent Issue Date Used in PTA Calculation
Critical | 01 Jul, 2008 | US7393543 |
| Issue Notification Mailed
Critical | 11 Jun, 2008 | US7393543 |
US patents provide insights into the exclusivity only within the United States, but
Endometrin is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Endometrin's family patents as well as insights into
ongoing legal events
on those patents.
Endometrin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Endometrin's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 17, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Endometrin Generic API suppliers:
Progesterone is the generic name for the brand Endometrin. 11 different companies have already filed for the generic of Endometrin, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Endometrin's generic
Alternative Brands for Endometrin
Endometrin which is used for supporting embryo implantation and early pregnancy in infertile women undergoing assisted reproductive technology (ART) treatment., has several other brand drugs using the same active ingredient (Progesterone). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Abbvie |
| ||
| Covis |
| ||
| Ferring Pharms Inc |
| ||
| Mayne Pharma |
| ||
| Pfizer |
| ||
| Wyeth Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Progesterone, Endometrin's active ingredient. Check the complete list of approved generic manufacturers for Endometrin
About Endometrin
Endometrin is a drug owned by Ferring Pharmaceuticals Inc. It is used for supporting embryo implantation and early pregnancy in infertile women undergoing assisted reproductive technology (ART) treatment. Endometrin uses Progesterone as an active ingredient. Endometrin was launched by Ferring in 2007.
Approval Date:
Endometrin was approved by FDA for market use on 21 June, 2007.
Active Ingredient:
Endometrin uses Progesterone as the active ingredient. Check out other Drugs and Companies using Progesterone ingredient
Treatment:
Endometrin is used for supporting embryo implantation and early pregnancy in infertile women undergoing assisted reproductive technology (ART) treatment.
Dosage:
Endometrin is available in insert form for vaginal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | INSERT | Prescription | VAGINAL |